Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
P/B ratio for Minerva Neurosciences, Inc. (NERV)
P/B ratio as of 2023: -1.41
According to Minerva Neurosciences, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -1.41. At the end of 2022 the company had a P/B ratio of -0.42.
P/B ratio history for Minerva Neurosciences, Inc. from 2012 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -1.41 |
| 2022 | -0.42 |
| 2021 | 4.29 |
| 2020 | 1.81 |
| 2019 | 9.99 |
| 2018 | 2.90 |
| 2017 | 1.74 |
| 2016 | 3.49 |
| 2015 | 2.57 |
| 2014 | 1.49 |
| 2013 | 5.48 |
| 2012 | 5814.31 |